Seed Round Now Open – January 2026

As of January 2026, DRUiD has officially opened its Seed Round.

Following key milestones in scientific verification, leadership growth, and prototype development in 2025.

We’re now seeking mission-aligned investors to support our next phase.

Funding will accelerate:

• Clinical trials and regulatory engagement with notified bodies

• Manufacturing scale-up of our beach head product for mastitis in cows.

• Expansion into our humanhealth applications (e.g., UTI/AST test)

  
  

This is a unique opportunity to invest in a high-potential diagnostic platform tackling one of the biggest health challenges of our time—antimicrobial resistance.

Interested investors or partners can get in touch directly with our CEO David Howarth.